Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$53.10 USD

53.10
4,689,021

+1.90 (3.71%)

Updated Jul 25, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 24% (191 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why Sanofi (SNY) is a Great Dividend Stock Right Now

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sanofi (SNY) have what it takes? Let's find out.

Glaxo, CureVac to Develop mRNA Vaccines for Infectious Disease

by Zacks Equity Research

Glaxo (GSK) signs a pact with CureVac for the development/commercialization of mRNA-based vaccines and monoclonal antibodies aimed at infectious disease pathogens.

Can Pfizer (PFE) Deliver a Beat in Coronavirus-Hit Q2 Earnings?

by Zacks Equity Research

Investor focus is likely to be on the extent of the impact of the coronavirus outbreak on Pfizer's (PFE) performance when it reports second-quarter results.

Biogen (BIIB) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Investor focus is likely to be on the extent of the impact of the coronavirus outbreak on Biogen's (BIIB) second-quarter earnings.

Sheraz Mian headshot

Top Analyst Reports for Netflix, AstraZeneca & Union Pacific

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Netflix (NFLX), AstraZeneca (AZN) and Union Pacific (UNP).

Daniel Laboe headshot

What To Expect From The Crazy Earnings Season Ahead

by Daniel Laboe

Are Netflix's disappointing results a foreshadowing of what is to come from the most parabolic tech stocks this earnings season?

The Zacks Analyst Blog Highlights: Moderna, BioNTech, Pfizer, GlaxoSmithKline and Sanofi

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Moderna, BioNTech, Pfizer, GlaxoSmithKline and Sanofi

Tirthankar Chakraborty headshot

Markets Bet Big on Coronavirus Vaccine Stocks: 3 Front Runners

by Tirthankar Chakraborty

As investors cheer signs of progress in COVID-19 vaccine development, here're three stocks that are worth keeping an eye on.

Ritujay Ghosh headshot

FDA Aims to Fast-Track Coronavirus Vaccine: 3 Stocks in Focus

by Ritujay Ghosh

Vaccine seems to be the only hope now to counter the pandemic given that millions of new cases of coronavirus are being reported every day.

Novo Nordisk's Shares Rise on New Approvals, Strong Portfolio

by Zacks Equity Research

Shares of Novo Nordisk (NVO) rally on solid product portfolio aided by new approvals.

The Zacks Analyst Blog Highlights: Oracle, Abbott Laboratories, Chevron, Sanofi and Boeing

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Oracle, Abbott Laboratories, Chevron, Sanofi and Boeing

J&J (JNJ) to Kickstart Q2 Earnings for the Pharma Sector

by Zacks Equity Research

Investor focus is likely to be on the impact of the coronavirus outbreak on J&J's (JNJ) performance when it reports second-quarter results.

Mylan (MYL) Obtains FDA Approval for Biosimilar of Humira

by Zacks Equity Research

Mylan's (MYL) biosimilars portfolio gets a boost with the FDA approval of Hulio, a biosimilar of Humira.

Sheraz Mian headshot

Top Analyst Reports for Oracle, Abbott & Chevron

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Oracle (ORCL), Abbott Laboratories (ABT) and Chevron (CVX).

Glaxo Signs Another Deal to Develop a Coronavirus Vaccine

by Zacks Equity Research

Glaxo (GSK) collaborates with Medicago to develop a vaccine candidate for COVID-19 using Medicago's antigen and Glaxo's adjuvant system.

Regeneron Initiates Studies on Experimental Coronavirus Drug

by Zacks Equity Research

Regeneron (REGN) announces initiation of late-stage studies evaluating REGN-COV2 for the treatment and prevention of COVID-19.

Moderna Shares Lose Momentum After Meteoric Rise: Here's Why

by Zacks Equity Research

The encouraging progress with mRNA-based coronavirus vaccine drives meteoric rise in Moderna's (MRNA) shares. However, a rumored concern leads to correction.

Sanofi/Regeneron's Kevzara Fails in Phase III Coronavirus Study

by Zacks Equity Research

Sanofi (SNY) and Regeneron discontinue U.S.-based phase III coronavirus study on Kevzara following failure to achieve improvement in hospitalized patients with severe COVID-19 patients of statistical significance.

Kinjel Shah headshot

Pharma Stock Roundup: PFE's Coronavirus Vaccine Study, Approvals in Focus

by Kinjel Shah

Pfizer (PFE) releases promising early results from its COVID-19 vaccine study. Several new drug/line extensions get approval in the United States, EU and Japan.

Dr. Reddy's Inks Deal With Two Companies for Coronavirus Drug

by Zacks Equity Research

Dr. Reddy's (RDY) signs agreement with FUJIFILM Toyama Chemical and Global Response Aid for Avigan tablets for the potential treatment of COVID-19.

Sanofi (SNY) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Sanofi (SNY) closed at $51.08 in the latest trading session, marking a +0.33% move from the prior day.

Ritujay Ghosh headshot

3 Stocks to Buy as Companies Speed Up Vaccine Production

by Ritujay Ghosh

Although the FDA is yet to approve a drug or treatment for COVID-19, companies have already started ramping up manufacturing lines to meet global demand if any of the experimental vaccines succeed.

Sanofi (SNY) is a Top Dividend Stock Right Now: Should You Buy?

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sanofi (SNY) have what it takes? Let's find out.

Translate Bio Up on Vaccine Agreement Expansion With Sanofi

by Zacks Equity Research

Translate Bio (TBIO) and Sanofi expand their tie-up to develop mRNA vaccines for infectious diseases. The deal boosts the company's cash resources significantly along with potential future revenues.

Company News for Jun 24, 2020

by Zacks Equity Research

Companies In The News Are: SPR, BA, EA, TBIO, SNY, MYOV.